Mei Feng

Dr. Mei Feng


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
MFMei Feng
Mei Feng
YJYiru Jin
Yiru Jin
SYSihyung Yang
Sihyung Yang
AJArline M. Joachim
Arline M. Joachim
YNYu Ning
Yu Ning
MWMichael Zhuo Wang
Michael Zhuo Wang
Human leishmaniasis is an infectious disease caused by Leishmania protozoan parasites. Current chemotherapeutic options against the deadly disease have significant limitations. The ergosterol biosynthetic pathway has been identified as a drug target in Leishmania. However, remarkable differences in the efficacy of antifungal azoles that inhibit ergosterol biosynthesis have been reported for the treatment of leishmaniasis. To better understand the sterol biosynthetic pathway in Leishmania and elucidate the mechanism underlying the differential efficacy of antifungal azoles, we developed a new LC-MS/MS method to study sterol profiles in promastigotes of three Leishmania species, including two L. donovani, one L. major and one L. tarentolae strains. A combination of distinct precursor ion masses and LC retention times allowed for specific detection of sixteen intermediate sterols between lanosterol and ergosterol using the newly developed LC-MS/MS method. Although both posaconazole and fluconazole are known inhibitors of fungal lanosterol 14α-demethylase (CYP51), only posaconazole led to a substantial accumulation of lanosterol in azole-treated L. donovani promastigotes. Furthermore, a key intermediate sterol accumulated by 40- and 7-fold when these parasites were treated with posaconazole and fluconazole, respectively, which was determined as 4α,14α-dimethylzymosterol by high resolution mass spectrometry and NMR spectroscopy. The identification of 4α,14α-dimethylzymosterol supports a branched ergosterol biosynthetic pathway in Leishmania, where lanosterol C4- and C14-demethylation reactions occur in parallel rather than sequentially. Our results suggest that selective inhibition of leishmanial CYP51 is insufficient to effectively prevent parasite growth and dual inhibitors of both CYP51 and the unknown sterol C4-demethylase may be required for optimal antiparasitic effect.

31 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YJYiru Jin
Yiru Jin
SBSomrita Basu
Somrita Basu
MFMei Feng
Mei Feng
YNYu Ning
Yu Ning
IMIndeewara Munasinghe
Indeewara Munasinghe
MWMichael Zhuo Wang
Michael Zhuo Wang
Visceral leishmaniasis is a life-threatening parasitic disease, but current antileishmanial drugs have severe drawbacks. Antifungal azoles inhibit the activity of cytochrome P450 (CYP) 51 enzymes which are responsible for removing the C14α-methyl group of lanosterol, a key step in ergosterol biosynthesis in Leishmania. However, they exhibit varying degrees of antileishmanial activities in culture, suggesting the existence of unrecognized molecular targets. Our previous study reveals that, in Leishmania, lanosterol undergoes parallel C4- and C14-demethylation to form 4α,14α-dimethylzymosterol and T-MAS, respectively. In the current study, CYP5122A1 is identified as a sterol C4-methyl oxidase that catalyzes the sequential oxidation of lanosterol to form C4-oxidation metabolites. CYP5122A1 is essential for both L. donovani promastigotes in culture and intracellular amastigotes in infected mice. CYP5122A1 overexpression results in growth delay, increased tolerance to stress, and altered expression of lipophosphoglycan and proteophosphoglycan. CYP5122A1 also helps to determine the antileishmanial effect of antifungal azoles in vitro. Dual inhibitors of CYP51 and CYP5122A1 possess superior antileishmanial activity against L. donovani promastigotes whereas CYP51-selective inhibitors have little effect on promastigote growth. Our findings uncover the critical biochemical and biological role of CYP5122A1 in L. donovani and provide an important foundation for developing new antileishmanial drugs by targeting both CYP enzymes.

7 April 2011 in Neurosignals
Verified
Journal Article
Open access
KJKewen Jiang
Kewen Jiang
JWJiangping Wang
Jiangping Wang
CZCongying Zhao
Congying Zhao
MFMei Feng
Mei Feng
ZSZheng Shen
Zheng Shen
ZXZhezhi Xia
Zhezhi Xia
It is known that neuronal ATP-sensitive potassium (K(ATP)) channels and astrocytic gap junctions (GJs) are involved in the mechanism underlying neurodisorders. The K(ATP) channels exist also in glial cells, and the objective of this study was to determine whether the astrocytic K(ATP) channels exert their effect on neurotoxin-induced neurodysfunction through regulating the astrocytic GJ function. The results showed that diazoxide, a selective mitochondrial K(ATP) (mitoK(ATP)) channel opener, enhanced the GJ coupling, but 5-hydroxydecanoate, a selective mitoK(ATP) channel blocker that significantly inhibits GJ coupling in vitro did not. Activation of astrocytic mitoK(ATP) channels alleviated kainic acid-induced dysfunction of GJ intercellular communication. Finally, activation of mitoK(ATP) channels improved the astrocytic GJ coupling in the hippocampus after seizures due to the colabeling of GJ subunit connexin 43 and connexin 45 with glial marker and was increased substantially by the administration of diazoxide. Western blot demonstrated that the mitoK(ATP) channels regulated the expression of connexin 43 (P2; active form) and connexin 45 in the epileptic hippocampus. These findings demonstrate that activation of astrocytic mitoK(ATP) channels improves the GJ function in astrocytes, indicating that the effect of the astrocytic mitoK(ATP) channels on neurotoxin-induced neurodysfunction might be, in part, through the regulation of the GJ-coupled spatial buffering in the hippocampus.

Verified
Journal Article
Open access
PDF file
YNYu Ning
Yu Ning
SBSomrita Basu
Somrita Basu
FHFONG HSU
FONG HSU
MFMei Feng
Mei Feng
MWMichael Zhuo Wang
Michael Zhuo Wang
KZKai Zhang
Kai Zhang
Sterol biosynthesis requires the oxidative removal of two methyl groups from the C-4 position by sterol C-4-demethylase and one methyl group from the C-14 position by sterol C-14-demethylase. In Leishmania donovani, a CYP5122A1 (Cytochrome P450 family 5122A1) protein was recently identified as the bona fide sterol C-4 methyl oxidase catalyzing the initial steps of C-4-demethylation. Besides CYP5122A1, Leishmania parasites possess orthologs to ERG25 (ergosterol pathway gene 25), the canonical sterol C-4 methyl oxidase in Saccharomyces cerevisiae. To determine the contribution of CYP5122A1 and ERG25 in sterol biosynthesis, we assessed the essentiality of these genes in Leishmania major, which causes cutaneous leishmaniasis. Like in L. donovani, CYP5122A1 in L. major could only be deleted in the presence of a complementing episome. Even with strong negative selection, L. major chromosomal CYP5122A1-null mutants retained the complementing episome in both promastigote and amastigote stages, demonstrating its essentiality. In contrast, the L. major ERG25-null mutants were fully viable and replicative in culture and virulent in mice. Deletion and overexpression of ERG25 did not affect the sterol composition, indicating that ERG25 is not required for C-4-demethylation. These findings suggest that CYP5122A1 is the dominant and possibly only sterol C-4 methyl oxidase in Leishmania, and inhibitors of CYP5122A1 may have strong therapeutic potential against multiple Leishmania species.

3 January 2026 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
ZAZahraa Al-Tamimi
Zahraa Al-Tamimi
MFMei Feng
Mei Feng
WEWaleed Elballa
Waleed Elballa
SHSydney Houser
Sydney Houser
MHMichael J. Hageman
Michael J. Hageman
Despite significant advancements in peptide drug development, there is still a challenge in formulating and delivering peptide drugs orally. Current oral peptide drugs have very low bioavailability (<1%), which could be attributed, in part, to enzymatic instability, poor membrane permeability/flux, and the sequestration by intestinal colloids composed of bile acid and phospholipids that form bile acid-phospholipid mixed micelles (BAPMM). In this work, we examined the effect of perturbing the BAPMM with bile acid sequestrants (BAS) on the membrane flux and enzymatic stability of octreotide in vitro, and its potential impact on peptide absorption and bioavailability in vivo. Additionally, we tested the effect of adding cyclic E-cadherin peptide (ECP) permeation enhancers on the bioavailability of octreotide. The results suggest that using BAS decreases the bile acid levels and putatively disrupts the micellar structure, leading to a higher concentration of the free peptide to diffuse across the membrane. In vitro bile acid sequestration enhanced the overall peptide flux rate without compromising the improved enzymatic stability. Our in vivo data suggests that using the BAS, colestipol, did not have a significant impact on peptide absorption though. These results highlight the important role of BAPMM on bioaccessible drug concentration, as well as membrane permeation.

2 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
YNYu Ning
Yu Ning
SBSomrita Basu
Somrita Basu
FHFONG HSU
FONG HSU
MFMei Feng
Mei Feng
MWMichael Zhuo Wang
Michael Zhuo Wang
KZKai Zhang
Kai Zhang
Background: Despite progress in access to family planning services in many sub-Saharan 11 African countries in recent decades, advances in early postpartum contraceptive adoption remain 12 low, and the unmet need for early postpartum contraceptives is high. According to the Ethiopia 13 Demographic and Health Survey report, early postpartum modern contraceptive method uptake is 14 still unacceptably low in Ethiopia. Objectives: This study aimed to determine the magnitude of 15 intention to adoption of early postpartum modern contraceptive methods and its associated factors 16 among pregnant women in Dessie and Kombolcha town zones, northeast Ethiopia. Methods: A 17 community-based cross-sectional study was deployed from January 15–February 15, 2023, in the 18 Dessie and Kombolcha zones, north-east Ethiopia among pregnant women. The study involved 780 19 pregnant women using the cluster sampling technique. A census was conducted in 20 randomly 20 selected clusters to identify eligible pregnant women. Actual data were collected home-to-home in 21 the community through face-to-face interviews. Data were collected by Open Data Kit (ODK) and 22 exported to STATA 17 for analysis. A multivariable logistic regression analysis was done and the 23 goodness of the model was checked by Hosmer-Lemeshow's test statistic and rock curve. An ad- 24 justed odds ratio with a 95% confidence interval and P-value < 0.05 was considered statistically sig- 25 nificant. Result: The study revealed that 49.6% of pregnant women lack autonomy and 50% lack 26 knowledge about early postpartum contraception, with participants' wealth index status ranging 27 from rich (36.6%) to poor (33.2%). The study found that 75.8% of pregnant women intended to adopt 28 early postpartum modern contraceptive methods early after childbirth. After controlling the poten- 29 tial confounder’s mothers age (AOR = 6.2 [2.6–14.6], birth interval (AOR = 2.5 [1.6–3.7]), have paid 30 work (AOR = 1.9 [1.3–2.8]), health facility from home (AOR=2.6[1.5-4.4]), last delivery 31 Place(AOR=2.4[1.1-5.7]), knowledge on (AOR = 1.5 [1.1-2.1]), and antenatal care follow-up (AOR = 32 1.9 [1.2-3.3]) were significant associated factors of intention to uptake early postpartum modern con- 33 traceptive methods among pregnant women. Conclusion: The study found that 75% of the partici- 34 pants had the intention to adoption of contraceptive methods during the early postpartum period. 35 Identified factors influencing this intention were age, birth interval, women's employment status, 36 area of residence, distance to health facilities, last delivery place, knowledge of early postpartum 37 modern contraception, gravidity, and antenatal care follow-up. These findings highlight the need 38 for targeted interventions to address these factors, framing the intended users and enabling access 39 to early adoption of postpartum contraceptive methods.